MiRagen Therapeutics, a Boulder-based company specializing in therapeutics based on small ribonucleic acid molecules, on Tuesday announced it inked a research, development and commercialization agreement worth more than $350 million.
MiRagen and Les Laboratoires Servier signed a partnership agreement under which Servier would fund the research, development and commercialization of three of drug candidates to treat cardiovascular disease. The agreement includes two of MiRagen’s lead programs and one yet-to-be-determined discovery target.
It’s a “transformational deal” for the fledgling MiRagen, a company that raised $18 million in venture capital since its 2007 founding, said William S. Marshall, MiRagen’s chief executive officer.
Read the rest of this report at .
